951 related articles for article (PubMed ID: 18046926)
21. Premixed insulin treatment for type 2 diabetes: analogue or human?
Garber AJ; Ligthelm R; Christiansen JS; Liebl A
Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
[TBL] [Abstract][Full Text] [Related]
22. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents.
Sakharova OV; Lleva RR; Dziura JD; Spollett GR; Howell SK; Beisswenger PJ; Inzucchi SE
J Diabetes Complications; 2012; 26(4):333-8. PubMed ID: 22541894
[TBL] [Abstract][Full Text] [Related]
23. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
[TBL] [Abstract][Full Text] [Related]
24. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
25. Premixed Insulin Analogue Compared with Basal-Plus Regimen for Inpatient Glycemic Control.
Gracia-Ramos AE; Cruz-Domínguez MD; Madrigal-Santillán EO; Morales-González JA; Madrigal-Bujaidar E; Aguilar-Faisal JL
Diabetes Technol Ther; 2016 Nov; 18(11):705-712. PubMed ID: 27860499
[TBL] [Abstract][Full Text] [Related]
26. The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub-analysis from the A(1)chieve(®) study.
Hwang YC; Kang JG; Ahn KJ; Cha BS; Ihm SH; Lee S; Kim M; Lee BW
Int J Clin Pract; 2014 Nov; 68(11):1338-44. PubMed ID: 25284679
[TBL] [Abstract][Full Text] [Related]
27. Insulin glargine.
Campbell RK; White JR; Levien T; Baker D
Clin Ther; 2001 Dec; 23(12):1938-57; discussion 1923. PubMed ID: 11813930
[TBL] [Abstract][Full Text] [Related]
28. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Madenidou AV; Paschos P; Karagiannis T; Katsoula A; Athanasiadou E; Kitsios K; Bekiari E; Matthews DR; Tsapas A
Ann Intern Med; 2018 Aug; 169(3):165-174. PubMed ID: 29987326
[TBL] [Abstract][Full Text] [Related]
29. Humalog (lispro) for type 2 diabetes.
Esposito K; Capuano A; Giugliano D
Expert Opin Biol Ther; 2012 Nov; 12(11):1541-50. PubMed ID: 23043233
[TBL] [Abstract][Full Text] [Related]
30. Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.
Lavernia F
Postgrad Med; 2010 May; 122(3):28-32. PubMed ID: 20463411
[TBL] [Abstract][Full Text] [Related]
31. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
[TBL] [Abstract][Full Text] [Related]
32. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
[TBL] [Abstract][Full Text] [Related]
33. Insulin analogues.
Marks J
Postgrad Med; 2002 Nov; 112(5 Suppl Designer):8-12. PubMed ID: 19667599
[TBL] [Abstract][Full Text] [Related]
34. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
[TBL] [Abstract][Full Text] [Related]
35. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
36. Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D.
Blevins T; Zhang Q; Frias JP; Jinnouchi H; Chang AM;
Diabetes Care; 2020 Dec; 43(12):2991-2998. PubMed ID: 32616612
[TBL] [Abstract][Full Text] [Related]
37. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials.
Esposito K; Chiodini P; Capuano A; Petrizzo M; Improta MR; Giugliano D
Diabetes Care; 2012 Dec; 35(12):2698-705. PubMed ID: 23173139
[TBL] [Abstract][Full Text] [Related]
38. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.
Fullerton B; Siebenhofer A; Jeitler K; Horvath K; Semlitsch T; Berghold A; Plank J; Pieber TR; Gerlach FM
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD012161. PubMed ID: 27362975
[TBL] [Abstract][Full Text] [Related]
39. Novel insulins: expanding options in diabetes management.
Gerich JE
Am J Med; 2002 Sep; 113(4):308-16. PubMed ID: 12361817
[TBL] [Abstract][Full Text] [Related]
40. Insulin detemir: a review of its use in the management of diabetes mellitus.
Keating GM
Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
